Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study

Sung Hyun Kim, Min Jung Lee, Ho Kyung Hwang, Sung Hwan Lee, Hoguen Kim, Young Ki Paik, Chang Moo Kang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel. OBJECTIVE: We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients. METHODS: From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048). CONCLUSION: Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.

Original languageEnglish
Pages (from-to)335-342
Number of pages8
JournalCancer Biomarkers
Volume24
Issue number3
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Complement Factor B
Pancreatic Neoplasms
Disease-Free Survival
Survival Rate
Survival Analysis
Tumor Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Kim, Sung Hyun ; Lee, Min Jung ; Hwang, Ho Kyung ; Lee, Sung Hwan ; Kim, Hoguen ; Paik, Young Ki ; Kang, Chang Moo. / Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer : A pilot study. In: Cancer Biomarkers. 2019 ; Vol. 24, No. 3. pp. 335-342.
@article{41a3a43db4354480994ccfabdc76e6fb,
title = "Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study",
abstract = "For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel. OBJECTIVE: We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients. METHODS: From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048). CONCLUSION: Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.",
author = "Kim, {Sung Hyun} and Lee, {Min Jung} and Hwang, {Ho Kyung} and Lee, {Sung Hwan} and Hoguen Kim and Paik, {Young Ki} and Kang, {Chang Moo}",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/CBM-181847",
language = "English",
volume = "24",
pages = "335--342",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "3",

}

Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer : A pilot study. / Kim, Sung Hyun; Lee, Min Jung; Hwang, Ho Kyung; Lee, Sung Hwan; Kim, Hoguen; Paik, Young Ki; Kang, Chang Moo.

In: Cancer Biomarkers, Vol. 24, No. 3, 01.01.2019, p. 335-342.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer

T2 - A pilot study

AU - Kim, Sung Hyun

AU - Lee, Min Jung

AU - Hwang, Ho Kyung

AU - Lee, Sung Hwan

AU - Kim, Hoguen

AU - Paik, Young Ki

AU - Kang, Chang Moo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel. OBJECTIVE: We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients. METHODS: From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048). CONCLUSION: Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.

AB - For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel. OBJECTIVE: We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients. METHODS: From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048). CONCLUSION: Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.

UR - http://www.scopus.com/inward/record.url?scp=85064379156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064379156&partnerID=8YFLogxK

U2 - 10.3233/CBM-181847

DO - 10.3233/CBM-181847

M3 - Article

C2 - 30829612

AN - SCOPUS:85064379156

VL - 24

SP - 335

EP - 342

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 3

ER -